The Ion AmpliSeq™ BRCA1 and BRCA2 community panel contains primer pairs that target the coding regions of the tumor suppressor genes BRCA1 and BRCA2, which have been implicated in hereditary breast and ovarian cancers. This research panel was designed with input from leading researchers from Radboud University Nijmegen Medical Centre, The Netherlands,1 and the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Portugal.2 The panel was further verified with input from a community of leading cancer researchers from various global research institutes that have been utilizing Ion Torrent’s complete NGS solution, from the Ion AmpliSeq™ BRCA gene panel to characterization of variants using Ion Reporter™ Software. .
These researchers, as part of the Life Technologies Consortium, use their expertise within specific disease research areas to create comprehensive, collaborative, and relevant gene panels featuring Ion AmpliSeq™ technology. Representing different international translational research institutions, these researchers bring many years of experience adopting the latest DNA sequencing and genotyping technologies to pioneering various disease research areas.
The verified performance of the Ion AmpliSeq™ BRCA1 and BRCA2 community panel design on over 150 unique samples previously screened using orthogonal technologies, combined with the affordability of Ion semiconductor sequencing and Ion AmpliSeq™ technology, creates a complete solution for cancer researchers, including:
Dr. Marjolijn Ligtenberg1
Dr. Arjen Mensenkamp1
Dr. José Carlos Machado2
Dr. José Luis Costa2
1 Radboud University Nijmegen Medical Centre, The Netherlands
2 The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Portugal
BRCA Consortia MembersDr. Arif B. Ekici
Institute of Human Genetics Friedrich-Alexander-University of Erlangen-Nürnberg, Germany
Feilotter Department of Pathology at Queen's University, Ontario Canada
Dr. Alfredo Hidalgo Miranda
National Institute of Genomic Medicine. Mexico City, Mexico
Prof. Jeffrey N. Weitzel
Division of Clinical Cancer Genetics City of Hope Cancer Center. Los Angeles
Dr. Nicola Williams
Southern General Hospital Glasgow, Scotland
Exploring the role of cancer gene panels and NGS in clinical research
View On Demand webinar
Genetic testing methods for cancer research play an important role detecting gene variance in disease. As researchers learn more about the mechanisms of cancer, the development of accurate and affordable technologies for effective and quick detection becomes paramount. Advances in next generation sequencing (NGS) have allowed accurate variant detection that can uncover the specific genetic mutations that may drive cancer. The application of NGS to breast cancer research has enabled the development of cost-effective, multi-gene sequencing panels that have advanced our understanding of the disease and may in the future translate into better diagnoses and outcomes for patients. The audience will learn about the current state of breast cancer research, how data generated by NGS gene panels target variants of interest and have been developed and used in routine laboratory research, and the broader issues of breast cancer education, awareness, and community services.
How to Design and Order Ion AmpliSeq™ Panels
The Ion AmpliSeq™ BRCA1 and BRCA2 Panel and other Ion AmpliSeq™ community panel designs may be reviewed and ordered via the Ion AmpliSeq™ Designer at ampliseq.com. Ordering is as easy as:
1. Creating an account by going to the Ion Community
2. Log in to ampliseq.com using your Ion Community account
3. Select “Panels tab” and then the “community panels” sub tab to review panel design and order
For Research Use Only. Not for use in diagnostic procedures.